IVERIC bio Inc

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

IVERIC bio, Inc. (NASDAQ:ISEE ) Q2 2022 Earnings Conference Call July 26, 2022 8:00 AM ET Company Participants Kathy Galante - SVP of IR Glenn Sblendorio - CEO Pravin Dugel - President Keith Westby - COO David Carroll - CFO Dhaval Desai - Chief Development Officer Chris Simms - Chief Commercial Officer Tony Gibney - Chief Business and Strategy Officer Conference Call Participants Mike Ulz - Morgan Stanley Annabel Samimy - Stifel Greg Harrison - Bank of America Ken Cacciatore - Cowen and Company Eddie Hickman - Guggenheim Securities Kambiz Yazdi - Jefferies Colleen Kusy - Baird Operator Good morning, and welcome to the IVERIC bio Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2022 Results - Earnings Call Transcript

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update.

Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results

Hercules Capital

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that it has entered into a term loan debt financing facility with Hercules Capital, Inc. and Silicon Valley Bank.

Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022.

Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric presented results from a post-hoc analysis from the GATHER1 clinical trial of Zimura at American Society of Retina Specialists Meeting.

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting

Fate Therapeutics

Karuna Therapeutics Inc

Madrigal Pharmaceuticals

Nkarta, Inc.

Seagen

Takeda Pharmaceutical

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.

Trial Results Set to Make or Break Small-Cap Pharma Stocks

PARSIPPANY, N.J. & TURKU, Finland--(BUSINESS WIRE)--Iveric entered into a global license agreement with DelSiTech to develop new formulations of Zimura using DelSiTech's sustained release technology.

Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®

Today, we take our first look at ocular focused biotech IVERIC bio, Inc. The stock has seen some insider buying here in June and its primary asset Zumira seems on the path to commercialization.

IVERIC bio: A First Take

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced its presentation of a post-hoc analysis from the Zimura GATHER1 clinical trial at the Macula Society Meeting in Berlin, Germany.

Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

Arbutus Biopharma

ContraFect

Eiger BioPharmaceuticals

Eli Lilly

Pfizer

SQZ Biotechnologies

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that Pravin U. Dugel, M.D., will participate in a fireside chat at the UBS Global Healthcare Conference 2022 on May 23, 2022.

Iveric Bio to Present at the UBS Global Healthcare Conference 2022

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that Pravin U. Dugel, M.D., President, will present a corporate overview at the H.C. Wainwright Global Investment Conference.

Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference

IVERIC bio, Inc. (NASDAQ:ISEE ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Kathy Galante - SVP of IR Glenn Sblendorio - CEO Pravin Dugel - President Keith Westby - COO David Carroll - CFO Dhaval Desai - Chief Development Officer Chris Simms - Chief Commercial Officer Tony Gibney - Chief Business and Strategy Officer Conference Call Participants Georgi Yordanov - Cowen & Company Annabel Samimy - Stifel Tiago Fauth - Credit Suisse Chris Howerton - Jefferies Colleen Kusy - Baird Operator Hello, and welcome to the IVERIC bio, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, today's event is being recorded.

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the first quarter ended Mar. 31, 2022 and provided a general business update.

Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that a post-hoc analysis from its GATHER1 clinical trial of Zimura will be presented at Renal World Congress on May 13, 2022.

Iveric Bio Announces Presentation of Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022.

Iveric Bio to Report First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 4, 2022

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022.

Iveric Bio to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

Blueprint Medicines

SpringWorks Therapeutics Inc

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the back burner.

Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks

Liquidia Technologies Inc

Sensus Healthcare

Biotech has been the worst performing sector of the stock market across the past 12 months.

Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that Glenn P. Sblendorio, CEO, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7.

Iveric Bio to Present at the Cowen 42nd Annual Health Care Conference

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2021 Results - Earnings Call Transcript

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2021 and provided a general business update.

Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022.

Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced a post-hoc analysis from the GATHER1 Zimura Phase 3 clinical trial, which evaluated various GA growth parameters.

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

NEW YORK--(BUSINESS WIRE)--Iveric announced that new post-hoc analyses from the GATHER1 Zimura® Phase 3 trial will be presented at Angiogenesis, Exudation, and Degeneration 2022

News for IVERIC bio Inc Stock (ISEE)